0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Complement Factor D

Complement Factor D

Brief Information

Name:Complement factor D
Target Synonym:EC 3.4.21,EC 3.4.21 );,C3 Convertase Activator,ADIPSIN,D Component Of Complement (Adipsin),PFD,Complement Factor D Preproprotein,Complement Factor D (Adipsin),EC 3.4.21.46,ADN,CFD,Properdin factor D,DF,Complement factor D,EC:3.4.21.46
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Synonym Name

CFD,Adipsin,PFD,DF,Complement factor D

Background

Complement factor D (CFD) is also known as Adipsin, C3 convertase activator, Properdin factor D (PFD), which contains one peptidase S1 domain and belongs to the peptidase S1 family. CFD / Adipsin cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. CFD / Adipsin is a serine protease that stimulates glucose transport for triglyceride accumulation in fats cells and inhibits lipolysis. Defects in CFD / Adipsin are the cause of complement factor D deficiency which predisposes to invasive meningococcal disease.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Danicopan ACH-4471; ACH-0144471; ALXN-2040; ACH-CFDIS Approved Achillion Pharmaceuticals Inc Voydeya, VOYDEYA Japan Hemoglobinuria, Paroxysmal Alexion Pharmaceuticals Inc 2024-01-18 Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Glomerulonephritis, Membranoproliferative; Hepatic Insufficiency; Geographic Atrophy; Glomerulonephritis Details
Danicopan ACH-4471; ACH-0144471; ALXN-2040; ACH-CFDIS Approved Achillion Pharmaceuticals Inc Voydeya, VOYDEYA Japan Hemoglobinuria, Paroxysmal Alexion Pharmaceuticals Inc 2024-01-18 Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Glomerulonephritis, Membranoproliferative; Hepatic Insufficiency; Geographic Atrophy; Glomerulonephritis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Vemircopan ACH-0145228; ACH-5228; ALXN-2050 Phase 2 Clinical Achillion Pharmaceuticals Inc Myasthenia Gravis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Hepatic Insufficiency Details
BCX-9930 BCX-9930 Phase 2 Clinical Biocryst Pharmaceuticals Inc Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Glomerulonephritis Details
ACH-5548 ACH-5548; ACH-0145548 Phase 1 Clinical Achillion Pharmaceuticals Inc Autoimmune Diseases Details
BCX-10013 BCX-10013 Phase 1 Clinical Biocryst Pharmaceuticals Inc Hemoglobinuria, Paroxysmal Details
ALXN-2080 ALXN-2080 Phase 1 Clinical Alexion Pharmaceuticals Inc Details
Vemircopan ACH-0145228; ACH-5228; ALXN-2050 Phase 2 Clinical Achillion Pharmaceuticals Inc Myasthenia Gravis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Hepatic Insufficiency Details
BCX-9930 BCX-9930 Phase 2 Clinical Biocryst Pharmaceuticals Inc Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Glomerulonephritis Details
ACH-5548 ACH-5548; ACH-0145548 Phase 1 Clinical Achillion Pharmaceuticals Inc Autoimmune Diseases Details
BCX-10013 BCX-10013 Phase 1 Clinical Biocryst Pharmaceuticals Inc Hemoglobinuria, Paroxysmal Details
ALXN-2080 ALXN-2080 Phase 1 Clinical Alexion Pharmaceuticals Inc Details

This web search service is supported by Google Inc.

totop

Laisser un message